keyword
MENU ▼
Read by QxMD icon Read
search

Uterine serous cancer

keyword
https://www.readbyqxmd.com/read/28392124/surgical-pathological-findings-in-type-1-and-2-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study-on-gog-210-protocol
#1
William T Creasman, Shamshad Ali, David G Mutch, Richard J Zaino, Matthew A Powell, Robert S Mannel, Floor J Backes, Paul A DiSilvestro, Peter A Argenta, Michael L Pearl, Shashikant B Lele, Saketh R Guntupalli, Steven Waggoner, Nick Spirtos, John F Boggess, Robert P Edwards, Virginia L Filiaci, David S Miller
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancer patients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28390820/mortality-reduction-and-cost-effectiveness-of-performing-hysterectomy-at-the-time-of-risk-reducing-salpingo-oophorectomy-for-prophylaxis-against-serous-serous-like-uterine-cancers-in-brca1-mutation-carriers
#2
Laura J Havrilesky, Haley A Moss, Junzo Chino, Evan R Myers, Noah D Kauff
OBJECTIVE: To estimate the survival benefit and cost-effectiveness of performing hysterectomy during risk-reducing salpingo-oophorectomy (RRSO) for BRCA1 mutation carriers. METHODS: Based on a recent prospective cohort study indicating an elevated incidence of serous/serous-like uterine cancers among BRCA1 mutation carriers, we constructed a modified Markov decision model from a payer perspective to inform decisions about performance of hysterectomy during RRSO at age 40...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28375927/impact-of-chemotherapy-and-radiotherapy-on-management-of-early-stage-clear-cell-and-papillary-serous-carcinoma-of-the-uterus
#3
Julian C Hong, Jonathan Foote, Gloria Broadwater, Stéphanie Gaillard, Laura J Havrilesky, Junzo P Chino
OBJECTIVE: The aim of the study was to assess interaction of lymph node dissection (LND), adjuvant chemotherapy (CT), and radiotherapy (RT) in stage I uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCC). METHODS/MATERIALS: The National Cancer Data Base was queried for women diagnosed with International Federation of Gynecology and Obstetrics stage I UPSC and UCC from 1998 to 2012. Overall survival (OS) was estimated for combinations of RT and CT by the Kaplan-Meier method stratified by histology and LND...
May 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28357094/high-grade-serous-ovarian-cancer-3-years-after-bilateral-salpingectomy-a-case-report
#4
Emi Sato, Kentaro Nakayama, Masako Ishikawa, Kohei Nakamura, Tomoka Ishibashi, Satoru Kyo
Although epithelial ovarian cancer commonly originates from the ovarian surface epithelium and/or ovarian inclusion cysts, it was recently proposed that high-grade serous ovarian cancer (HGSC) develops from the Fallopian tubes. In our department, we encountered a case of HGSC that contradicts the hypothesis of a tubal origin for HGSC. A 51-year-old postmenopausal woman had undergone hysterectomy, left oophorectomy and bilateral salpingectomy for uterine myoma. Three years later, the patient was diagnosed with stage IV ovarian cancer and underwent primary debulking surgery...
February 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28343693/utility-of-radiation-therapy-for-early-stage-uterine-papillary-serous-carcinoma
#5
Stephanie Cham, Yongmei Huang, Ana I Tergas, June Y Hou, William M Burke, Israel Deutsch, Cande V Ananth, Alfred I Neugut, Dawn L Hershman, Jason D Wright
OBJECTIVE: Early-stage uterine papillary serous carcinoma (UPSC) has a poor prognosis and high recurrence rate. While adjuvant chemotherapy is generally recommended, the role of radiation is uncertain. We examined the association between vaginal brachytherapy and whole pelvic radiation and survival in women treated with and without adjuvant chemotherapy. METHODS: The National Cancer Data Base was used to identify women with stage I-II UPSC treated between 1998 and 2012...
March 23, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28319570/microcystic-elongated-and-fragmented-pattern-invasion-in-ovarian-endometrioid-carcinoma-immunohistochemical-profile-and-prognostic-implications
#6
Allison Goldberg, Lauren Hand, Dan DeCotiis, Norman Rosenblum, Joanna Chan
Microcystic, elongated, and fragmented (MELF) pattern invasion is a poor prognostic indicator in uterine endometrioid carcinoma, but its existence, biology, and prognostic value have not been described in ovarian endometrioid carcinoma. We evaluated cases of ovarian endometrioid carcinoma without synchronous uterine endometrioid carcinoma for MELF and other histologic features. To evaluate tumor biology, we assessed an immunohistochemical profile, including MLH1, PMS2, MSH2, MSH6, β-catenin, e-cadherin, CK19, and cyclin D1...
March 17, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28292439/integrated-molecular-characterization-of-uterine-carcinosarcoma
#7
Andrew D Cherniack, Hui Shen, Vonn Walter, Chip Stewart, Bradley A Murray, Reanne Bowlby, Xin Hu, Shiyun Ling, Robert A Soslow, Russell R Broaddus, Rosemary E Zuna, Gordon Robertson, Peter W Laird, Raju Kucherlapati, Gordon B Mills, John N Weinstein, Jiashan Zhang, Rehan Akbani, Douglas A Levine
We performed genomic, epigenomic, transcriptomic, and proteomic characterizations of uterine carcinosarcomas (UCSs). Cohort samples had extensive copy-number alterations and highly recurrent somatic mutations. Frequent mutations were found in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS, similar to endometrioid and serous uterine carcinomas. Transcriptome sequencing identified a strong epithelial-to-mesenchymal transition (EMT) gene signature in a subset of cases that was attributable to epigenetic alterations at microRNA promoters...
March 13, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28285341/improved-quality-of-risk-reducing-salpingo-oophorectomy-in-australasian-women-at-high-risk-of-pelvic-serous-cancer
#8
Y C Lee, M Bressel, P Grant, P Russell, C Smith, S Picken, S Camm, B E Kiely, R L Milne, S A McLachlan, M Hickey, M L Friedlander, J L Hopper, K A Phillips
OBJECTIVES: The quality of risk-reducing salpingo-oophorectomy (RRSO) performed in Australasian women was previously reported to be suboptimal. Here we describe the quality of RRSO performed since 2008 in women enrolled in the same cohort and determine whether it has improved. DESIGN: Prospective cohort study of women at high risk of pelvic serous cancer (PSC) in kConFab. Eligible women had RRSO between 2008 and 2014 and their RRSO surgical and pathology reports were reviewed...
March 11, 2017: Familial Cancer
https://www.readbyqxmd.com/read/28258415/survival-of-patients-with-serous-uterine-carcinoma-undergoing-sentinel-lymph-node-mapping
#9
Maria B Schiavone, Chiara Scelzo, Celeste Straight, Qin Zhou, Kaled M Alektiar, Vicky Makker, Robert A Soslow, Alexia Iasonos, Mario M Leitao, Nadeem R Abu-Rustum
OBJECTIVE: The aim of this study was to determine progression-free survival (PFS) in patients with serous uterine carcinoma undergoing sentinel lymph node (SLN) mapping compared with patients undergoing standard lymphadenectomy. METHODS: We retrospectively reviewed all uterine cancer patients treated at our institution from 2005 to 2015. Patients were separated into two cohorts: those who underwent SLN mapping at the time of staging (SLN) and those who underwent routine lymphadenectomy (the non-SLN group)...
March 3, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28247037/accuracy-of-pre-operative-hysteroscopic-guided-biopsy-for-predicting-final-pathology-in-uterine-malignancies
#10
Fabio Martinelli, Antonino Ditto, Giorgio Bogani, Mauro Signorelli, Valentina Chiappa, Domenica Lorusso, Edward Haeusler, Francesco Raspagliesi
PURPOSE: To evaluate concordance (C) between pre-operative hysteroscopic-directed sampling and final pathology in uterine cancers. METHODS: A retrospective cross-sectional evaluation of prospectively collected data of women who underwent hysterectomy for uterine malignancies and a previous hysteroscopic-guided biopsy was performed. Diagnostic concordance between pre-operative (hysteroscopic biopsy) and postoperative (uterine specimen) histology was evaluated. In endometrioid-endometrial cancers cases Kappa (k) statistics was applied to evaluate agreement for grading (G) between the preoperative and final pathology...
March 1, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28221216/l1cam-and-her2-expression-in-early-endometrioid-uterine-cancer
#11
Samira Abdel Azim, Susanne Sprung, Irene Mutz-Dehbalaie, Siegfried Fessler, Alain G Zeimet, Christian Marth
Recently L1CAM was shown to be a promising biomarker for early-stage endometrial carcinoma (EC). As L1CAM expression was found to be related to serous ECs and areas of serous differentiation in endometrioid carcinomas, there is evidence that L1CAM-positive cancers more likely resemble type II carcinomas. Furthermore, expression of growth factor receptor HER2 has been found to be closely associated with serous ECs. We conducted a retrospective study on 142 patients in FIGO stages I and II with endometrioid EC and analyzed L1CAM and HER2 expression by double-staining immunohistochemistry...
February 17, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28196634/objective-domain-specific-her2-measurement-in-uterine-and-ovarian-serous-carcinomas-and-its-clinical-significance
#12
Daniel E Carvajal-Hausdorf, Kurt A Schalper, Yalai Bai, Jonathan Black, Alessandro D Santin, David L Rimm
INTRODUCTION: HER2 overexpression/amplification is identified in up to 40% of uterine serous carcinomas (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents failed to show significant responses. FDA-approved HER2 assays target only the protein's intracellular domain (ICD) and not the extracellular domain (ECD). Previous quantitative studies in breast cancer by our group have shown that ICD of HER2 is expressed in some cases that do not express the HER2 ECD...
April 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28159409/disparities-in-receipt-of-care-for-high-grade-endometrial-cancer-a-national-cancer-data-base-analysis
#13
Amy J Bregar, J Alejandro Rauh-Hain, Ryan Spencer, Joel T Clemmer, John O Schorge, Laurel W Rice, Marcela G Del Carmen
PURPOSE: To examine patterns of care and survival for Hispanic women compared to white and African American women with high-grade endometrial cancer. METHODS: We utilized the National Cancer Data Base (NCDB) to identify women diagnosed with uterine grade 3 endometrioid adenocarcinoma, carcinosarcoma, clear cell carcinoma and papillary serous carcinoma between 2003 and 2011. The effect of treatment on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model...
February 1, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28118070/endometrial-cancer-with-congenital-uterine-anomalies-3-case-reports-and-a-literature-review
#14
Jinping Gao, Jintian Zhang, Wenyan Tian, Fei Teng, Huiying Zhang, Xuhong Zhang, Yingmei Wang, Fengxia Xue
BACKGROUND: Uterine malformation is a rare deformity in woman, and only a few cases concerning endometrial cancer arising in patients with congenital uterine anomalies have been reported. Herein, we present 3 cases of endometrial cancer with different congenital uterine anomalies, and review studies involving congenital uterine anomalies associated with endometrial cancer in the past 25 years, to identify similarities and differences in clinicopathologic characteristics and prognosis between endometrial cancer associated with uterine anomalies, and normal uterus...
March 4, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28112582/the-allosteric-akt-inhibitor-mk2206-decreases-tumor-growth-and-invasion-in-patient-derived-xenografts-of-endometrial-cancer
#15
Abigail Winder, Kenji Unno, Yanni Yu, John Lurain, J Julie Kim
The purpose of this study was to test the effect of MK2206, an allosteric inhibitor of AKT, on the growth and invasion of patient-derived xenografts (PDX) of endometrial cancer. Three PDX lines, USC1 (uterine serous), EEC2 (endometrioid grade 2) and EEC4 (endometrioid grade 3) of endometrial cancer were grafted under the renal capsule of NSG mice. After 2 weeks of tumor growth the mice were treated with vehicle or 120mg/kg MK2206 twice a week for three weeks. Growth of all three PDX lines of different type and grade was significantly inhibited in response to MK2206 compared to vehicle control...
January 23, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28106106/serous-tubal-intraepithelial-neoplasia-the-concept-and-its-application
#16
REVIEW
Emily E K Meserve, Jan Brouwer, Christopher P Crum
In recent years it has become clear that many extra-uterine (pelvic) high-grade serous carcinomas (serous carcinomas) are preceded by a precursor lesion in the distal fallopian tube. Precursors range from small self-limited 'p53 signatures' to expansile serous tubal intraepithelial neoplasms that include both serous tubal epithelial proliferations (or lesions) of uncertain significance and serous tubal intraepithelial carcinomas. These precursors can be considered from three perspectives. The first is biologic underpinnings, which are multifactorial, and include the intersection of DNA damage with Tp53 mutations and disturbances in transcriptional regulation that increase with age...
January 20, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28088687/whole-genome-dna-methylation-profiling-identifies-epigenetic-signatures-of-uterine-carcinosarcoma
#17
Jing Li, Xiaoyun Xing, Daofeng Li, Bo Zhang, David G Mutch, Ian S Hagemann, Ting Wang
Uterine carcinosarcoma (UCS) is a form of endometrial cancer simultaneously exhibiting carcinomatous and sarcomatous elements, but the underlying molecular and epigenetic basis of this disease is poorly understood. We generated complete DNA methylomes for both the carcinomatous and the sarcomatous components of three UCS samples separated by laser capture microdissection and compared DNA methylomes of UCS with those of normal endometrium as well as methylomes derived from endometrioid carcinoma, serous endometrial carcinoma, and endometrial stromal sarcoma...
February 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28062116/prior-breast-cancer-and-tamoxifen-exposure-does-not-influence-outcomes-in-women-with-uterine-papillary-serous-carcinoma
#18
Stuart R Pierce, Jessica E Stine, Paola A Gehrig, Laura J Havrilesky, Angeles A Secord, John Nakayama, Anna C Snavely, Dominic T Moore, Kenneth H Kim
OBJECTIVES: To evaluate progression-free survival (PFS) and overall survival (OS) outcomes in women diagnosed with uterine papillary serous carcinoma (UPSC) who have had (UPSCBR+) or have not had (UPSCBR-) an antecedent history of breast cancer and to correlate their outcomes to prior tamoxifen exposure. METHODS: Data were collected for women diagnosed with UPSC at two academic institutions between January 1997 and July 2012. Patient demographics, tumor histology, stage, and treatments were recorded...
March 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28049106/linking-uterine-serous-carcinoma-to-brca1-2-associated-cancer-syndrome-a-meta-analysis-and-case-report
#19
REVIEW
M M de Jonge, A L Mooyaart, M P G Vreeswijk, C D de Kroon, T van Wezel, C J van Asperen, V T H B M Smit, O M Dekkers, T Bosse
BACKGROUND: Uterine serous carcinoma (USC) shows greater morphological, clinical and molecular similarities to high-grade ovarian tubal serous carcinoma than to other types of endometrial cancer. As high-grade ovarian tubal serous carcinoma is known to be associated with BRCA1/2 pathogenic germline mutations (PMs), we aimed to explore whether USC is also a constituent of hereditary breast and ovarian cancer syndrome. METHODS: Pubmed, EMBASE and Web of Science were searched in July 2016 for articles assessing the association between USC and germline BRCA1/2-PMs...
December 31, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27965399/selenium-binding-protein-1-autoantibodies-in-ovarian-disorders-and-ovarian-cancer
#20
Yi Yu-Rice, Seby L Edassery, Nicole Urban, Ingegerd Hellstrom, Karl Eric Hellstrom, Youping Deng, Yan Li, Judith Luborsky
Infertility is a risk factor for ovarian cancer (OvCa). The goal was to determine if antibodies to Selenium Binding Protein 1 (SBP1), an autoantibody we identified in patients with premature ovarian failure (POF), occurs in both infertility and OvCa patients, and thus could be associated with preneoplasia. Anti-SBP1 was measured by immunoassay against recombinant SBP1, in sera from OvCa (n=41), infertility (n=92) and control (n=87) patients. Infertility causes were POF, unexplained, irregular ovulation or endometriosis...
December 13, 2016: Reproduction: the Official Journal of the Society for the Study of Fertility
keyword
keyword
16962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"